Aurobindo Must Sell 4 Drug Assets to Complete USD 250 Million Lannett Buyout, Says FTC
New Delhi: The U.S. Federal Trade Commission is requiring Aurobindo Pharma Limited to divest four different generic drug products to complete its $250 million acquisition of Lannett Company Inc., the agency said on Thursday in a statement.
The agency will require Aurobindo to divest to Quagen Pharmaceuticals an immunosuppressant prescribed to prevent organ transplant rejection, a cholesterol management drug, a drug prescribed to treat dry mouth in radiation therapy patients and a drug prescribed to reduce stomach acid.
"Aurobindo’s acquisition of Lannett would combine two of a limited number of competitors in the markets for four different generic pharmaceutical products that provide critical relief for patients, ranging from drugs used to prevent organ transplant rejection to tablets that treat dry mouth after radiation therapy," the FTC said.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.